A detailed history of Octagon Capital Advisors LP transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 666,825 shares of IPSC stock, worth $840,199. This represents 0.28% of its overall portfolio holdings.

Number of Shares
666,825
Previous 1,333,650 50.0%
Holding current value
$840,199
Previous $3.4 Million 66.47%
% of portfolio
0.28%
Previous 0.79%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.44 - $3.29 $960,228 - $2.19 Million
-666,825 Reduced 50.0%
666,825 $1.14 Million
Q2 2024

Aug 14, 2024

BUY
$2.46 - $4.05 $1.95 Million - $3.21 Million
793,650 Added 146.97%
1,333,650 $3.4 Million
Q1 2024

May 15, 2024

BUY
$3.19 - $5.32 $1.72 Million - $2.87 Million
540,000 New
540,000 $2.26 Million
Q4 2022

Feb 14, 2023

SELL
$4.84 - $11.58 $1.04 Million - $2.49 Million
-215,000 Reduced 82.69%
45,000 $230,000
Q2 2022

Aug 15, 2022

SELL
$7.96 - $12.43 $3.17 Million - $4.95 Million
-398,266 Reduced 60.5%
260,000 $2.18 Million
Q1 2022

May 16, 2022

SELL
$11.62 - $15.92 $515,428 - $706,163
-44,357 Reduced 6.31%
658,266 $8.29 Million
Q4 2021

Feb 14, 2022

BUY
$13.93 - $23.62 $1.39 Million - $2.36 Million
100,000 Added 16.59%
702,623 $11.1 Million
Q3 2021

Nov 15, 2021

BUY
$20.8 - $31.93 $4.14 Million - $6.36 Million
199,100 Added 49.34%
602,623 $15.2 Million
Q2 2021

Aug 16, 2021

BUY
$22.45 - $29.34 $9.06 Million - $11.8 Million
403,523 New
403,523 $11.8 Million

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $74.2M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.